Want to see FR:ALDVI full AI Analyst Report?
Top Page
Advicenne SA
(ALDVI)
Select Model
Select Model
Rating:37Underperform
Price Target:
€0.81
▼(-11.96% Downside)
Action:Downgraded
Date:09/19/26
The score is driven down primarily by weak financial performance (persistent losses, cash burn, and negative equity) and bearish technicals (price below all key moving averages with negative MACD). Valuation provides limited support due to a very high P/E and no dividend yield data.
Positive Factors
Rare-disease specialization
Focus on rare kidney and metabolic diseases gives Advicenne a defined specialty position, with Sibnayal addressing dRTA and other modified-release products extending its therapeutic capabilities. This specialization can support focused development and commercialization over the medium term.
Negative Factors
Negative equity
Persistent negative equity signals a fragile capital structure and materially reduces financial flexibility. Combined with sizable debt relative to assets, it may constrain investment choices and leave Advicenne more exposed when additional funding is required to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Rare-disease specialization
Focus on rare kidney and metabolic diseases gives Advicenne a defined specialty position, with Sibnayal addressing dRTA and other modified-release products extending its therapeutic capabilities. This specialization can support focused development and commercialization over the medium term.
Read all positive factors
Advicenne SA (ALDVI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€11.08M
Dividend YieldN/A
Average Volume (3M)127.78K
Price to Earnings (P/E)290.6
Beta (1Y)0.12
Revenue Growth0.10%
EPS Growth99.69%
CountryFR
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume90,276
30 Day Avg. Volume127,783
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€6.60M
Advicenne SA Business Overview & Revenue Model
Company Description
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubul...
How the Company Makes Money
Advicenne primarily makes money from (1) sales of its marketed medicines and (2) commercialization agreements that monetize its products through partners in certain geographies. A key revenue stream is product revenue from Sibnayal (ADV7103) in ma...
Advicenne SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.01M | 4.97M | 4.46M | 2.40M | 2.69M |
| Gross Profit | -922.00K | -1.18M | -6.31M | 1.28M | 1.72M |
| EBITDA | -7.81M | 1.30M | -6.24M | -9.87M | -12.04M |
| Net Income | -9.53M | -6.46M | -7.03M | -11.47M | -12.43M |
Balance Sheet | |||||
| Total Assets | 7.14M | 9.51M | 12.41M | 14.26M | 18.88M |
| Cash, Cash Equivalents and Short-Term Investments | 1.34M | 3.25M | 5.25M | 8.32M | 12.69M |
| Total Debt | 19.00M | 18.19M | 18.32M | 18.75M | 12.54M |
| Total Liabilities | 33.51M | 28.58M | 24.38M | 24.88M | 18.57M |
| Stockholders Equity | -26.37M | -19.07M | -11.97M | -10.50M | 309.00K |
Cash Flow | |||||
| Free Cash Flow | -4.11M | -853.00K | -7.27M | -9.26M | -12.82M |
| Operating Cash Flow | -3.73M | -762.00K | -5.99M | -9.15M | -12.53M |
| Investing Cash Flow | -403.00K | -108.00K | -1.32M | -2.00K | -395.00K |
| Financing Cash Flow | 2.23M | -1.13M | 4.23M | 4.78M | 8.85M |
Advicenne SA Technical Analysis
Negative
0.92
Price Trends
1.45
Negative
1.28
Negative
1.52
Negative
Market Momentum
-0.22
Positive
26.03
Positive
13.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALDVI, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.45, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 26.03 is Positive, neither overbought nor oversold. The STOCH value of 13.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALDVI.
Advicenne SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €25.62M | -1.34 | 42.20% | ― | -99.93% | 44.53% | |
44 Neutral | €95.02M | -1.88 | -58.01% | ― | ― | -5.59% | |
43 Neutral | €82.92M | -11.60 | -114.60% | ― | -10.72% | -21.24% | |
42 Neutral | €39.77K | -1.99 | -27.13% | ― | -44.46% | 100.00% | |
37 Underperform | €11.08M | 290.63 | -0.17% | ― | 0.10% | 99.69% |
* Healthcare Sector Average
FR:ALDVI
Advicenne SA
0.87
-0.40
-31.81%
FR:SIGHT
GenSight Biologics SA
0.11
-0.04
-28.00%
FR:ABNX
ABIONYX Pharma SA
1.83
-1.92
-51.20%
FR:ALSEN
Sensorion SAS
9.19
-6.11
-39.95%
FR:ALNEV
Neovacs SA
0.26
-2,498.74
-99.99%
Advicenne SA Corporate Events
Advicenne swings to profit as Sibnayal growth and French pricing deals cut debt
Sep 17, 2026
Advicenne reported a sharp improvement in its first-half 2026 performance, turning a €4.62 million net profit versus a loss a year earlier, driven by price agreements for Sibnayal and Likozam in France and strong growth in Sibnayal sales acr...
Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback
Aug 31, 2026
Advicenne has voluntarily withdrawn its New Drug Application to the U.S. Food and Drug Administration for ADV7103 in primary distal renal tubular acidosis, after regulators indicated that additional Chemistry, Manufacturing and Controls work is re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.